Fluticasone propionate 0.005%. Avoid use near eyes, on face, groin, or axillae. Do not use for diaper dermatitis, rosacea, perioral dermatitis, or on pre-existing skin atrophy. Avoid tight-fitting ...

Xhance (fluticasone propionate) is a prescription drug that’s used to treat chronic sinusitis. Xhance comes as a nasal spray. Xhance is used in adults to treat chronic (ongoing) sinusitis (sinus ...

The usual Xhance (fluticasone propionate) dosage for chronic sinus infection is 186 or 372 micrograms (mcg) twice daily. Dosages may vary depending on your symptoms and other medications. Always use ...

Doctors recommend fluticasone-containing medications to treat a range of conditions, including inflammatory skin conditions, allergies, and asthma. This article describes the forms of fluticasone, how ...

Please provide your email address to receive an email when new articles are posted on . The Exhalation Delivery System reaches inflamed areas of the nasal cavity and sinuses that other sprays miss.

Xhance (fluticasone propionate) is a brand-name drug that’s prescribed for chronic rhinosinusitis with or without nasal polyps in adults. Xhance comes as a nasal spray that’s typically used twice per ...

Please provide your email address to receive an email when new articles are posted on . An exhalation delivery system that uses fluticasone propionate nasal spray reduced the symptoms of chronic ...

Of the 435 patients recruited, 349 were randomised to treatment: 176 patients to the salmeterol/FP group and 173 to the BUD group. Of the 86 withdrawn before randomisation, 66 failed to fulfil the ...

An exhalation system with fluticasone was shown to significantly reduce nasal polyp score at 4 and 16 weeks compared with placebo, with improvements also observed in several patient-reported outcomes.

A total of 332 patients entered the study and 277 patients were randomised and treated, 137 with FP250µg twice daily via Diskus TM inhaler and 140 with budesonide 600µg twice daily via Turbuhaler TM.

High-dose fluticasone increases sputum bacterial load in severe COPD; ICS withdrawal is poorly tolerated, highlighting microbiome considerations in therapy.